Academic Journal
Live attenuated varicella-zoster virus vaccine does not induce HIV target cell activation.
| Τίτλος: | Live attenuated varicella-zoster virus vaccine does not induce HIV target cell activation. |
|---|---|
| Συγγραφείς: | Perciani, CT, Farah, B, Kaul, R, Ostrowski, MA, Mahmud, SM, Anzala, O, Jaoko, W, KAVI-ICR Team, MacDonald, KS |
| Στοιχεία εκδότη: | BMC |
| Έτος έκδοσης: | 2019 |
| Συλλογή: | University of Nairobi Digital Repository |
| Θεματικοί όροι: | AIDS vaccine, AIDS/HIV, Cytokines, T cells, Vaccines |
| Περιγραφή: | BACKGROUND: Varicella-zoster virus (VZV) is under consideration as a promising recombinant viral vector to deliver foreign antigens including HIV. However, new vectors have come under increased scrutiny, since trials with adenovirus serotype 5-vectored (Ad5-vectored) HIV vaccine demonstrated increased HIV risk in individuals with pre-immunity to the vector that was thought to be associated with mucosal immune activation (IA). Therefore, given the prospect of developing an HIV/VZV chimeric vaccine, it is particularly important to define the impact of VZV vaccination on IA. METHODS: Healthy VZV-seropositive Kenyan women (n = 44) were immunized with high-dose live attenuated VZV vaccine, and we assessed the expression on CD4+ T cells isolated from blood, cervix, and rectum of IA markers including CD38 and HLA-DR and of markers of cell migration and tissue retention, as well as the concentration of genital and intestinal cytokines. A delayed-start group (n = 22) was used to control for natural variations in these parameters. RESULTS: Although immunogenic, VZV vaccination did not result in significant difference in the frequency of cervical activated (HLA-DR+CD38+) CD4+ T cells (median 1.61%, IQR 0.93%-2.76%) at 12 weeks after vaccination when compared with baseline (median 1.58%, IQR 0.75%-3.04%), the primary outcome for this study. VZV vaccination also had no measurable effect on any of the IA parameters at 4, 8, and 12 weeks after vaccination. CONCLUSION: This study provides the first evidence to our knowledge about the effects of VZV vaccination on human mucosal IA status and supports further evaluation of VZV as a potential vector for an HIV vaccine. |
| Τύπος εγγράφου: | article in journal/newspaper |
| Περιγραφή αρχείου: | application/pdf |
| Γλώσσα: | English |
| Relation: | https://www.ncbi.nlm.nih.gov/pubmed/30511963; http://erepository.uonbi.ac.ke/handle/11295/106532 |
| Διαθεσιμότητα: | https://www.ncbi.nlm.nih.gov/pubmed/30511963 http://erepository.uonbi.ac.ke/handle/11295/106532 |
| Αριθμός Καταχώρησης: | edsbas.686E5322 |
| Βάση Δεδομένων: | BASE |
| FullText | Text: Availability: 0 CustomLinks: – Url: https://www.ncbi.nlm.nih.gov/pubmed/30511963# Name: EDS - BASE (ns324271) Category: fullText Text: View record from BASE |
|---|---|
| Header | DbId: edsbas DbLabel: BASE An: edsbas.686E5322 RelevancyScore: 813 AccessLevel: 3 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 813.215454101563 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Live attenuated varicella-zoster virus vaccine does not induce HIV target cell activation. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Perciani%2C+CT%22">Perciani, CT</searchLink><br /><searchLink fieldCode="AR" term="%22Farah%2C+B%22">Farah, B</searchLink><br /><searchLink fieldCode="AR" term="%22Kaul%2C+R%22">Kaul, R</searchLink><br /><searchLink fieldCode="AR" term="%22Ostrowski%2C+MA%22">Ostrowski, MA</searchLink><br /><searchLink fieldCode="AR" term="%22Mahmud%2C+SM%22">Mahmud, SM</searchLink><br /><searchLink fieldCode="AR" term="%22Anzala%2C+O%22">Anzala, O</searchLink><br /><searchLink fieldCode="AR" term="%22Jaoko%2C+W%22">Jaoko, W</searchLink><br /><searchLink fieldCode="AR" term="%22KAVI-ICR+Team%22">KAVI-ICR Team</searchLink><br /><searchLink fieldCode="AR" term="%22MacDonald%2C+KS%22">MacDonald, KS</searchLink> – Name: Publisher Label: Publisher Information Group: PubInfo Data: BMC – Name: DatePubCY Label: Publication Year Group: Date Data: 2019 – Name: Subset Label: Collection Group: HoldingsInfo Data: University of Nairobi Digital Repository – Name: Subject Label: Subject Terms Group: Su Data: <searchLink fieldCode="DE" term="%22AIDS+vaccine%22">AIDS vaccine</searchLink><br /><searchLink fieldCode="DE" term="%22AIDS%2FHIV%22">AIDS/HIV</searchLink><br /><searchLink fieldCode="DE" term="%22Cytokines%22">Cytokines</searchLink><br /><searchLink fieldCode="DE" term="%22T+cells%22">T cells</searchLink><br /><searchLink fieldCode="DE" term="%22Vaccines%22">Vaccines</searchLink> – Name: Abstract Label: Description Group: Ab Data: BACKGROUND: Varicella-zoster virus (VZV) is under consideration as a promising recombinant viral vector to deliver foreign antigens including HIV. However, new vectors have come under increased scrutiny, since trials with adenovirus serotype 5-vectored (Ad5-vectored) HIV vaccine demonstrated increased HIV risk in individuals with pre-immunity to the vector that was thought to be associated with mucosal immune activation (IA). Therefore, given the prospect of developing an HIV/VZV chimeric vaccine, it is particularly important to define the impact of VZV vaccination on IA. METHODS: Healthy VZV-seropositive Kenyan women (n = 44) were immunized with high-dose live attenuated VZV vaccine, and we assessed the expression on CD4+ T cells isolated from blood, cervix, and rectum of IA markers including CD38 and HLA-DR and of markers of cell migration and tissue retention, as well as the concentration of genital and intestinal cytokines. A delayed-start group (n = 22) was used to control for natural variations in these parameters. RESULTS: Although immunogenic, VZV vaccination did not result in significant difference in the frequency of cervical activated (HLA-DR+CD38+) CD4+ T cells (median 1.61%, IQR 0.93%-2.76%) at 12 weeks after vaccination when compared with baseline (median 1.58%, IQR 0.75%-3.04%), the primary outcome for this study. VZV vaccination also had no measurable effect on any of the IA parameters at 4, 8, and 12 weeks after vaccination. CONCLUSION: This study provides the first evidence to our knowledge about the effects of VZV vaccination on human mucosal IA status and supports further evaluation of VZV as a potential vector for an HIV vaccine. – Name: TypeDocument Label: Document Type Group: TypDoc Data: article in journal/newspaper – Name: Format Label: File Description Group: SrcInfo Data: application/pdf – Name: Language Label: Language Group: Lang Data: English – Name: NoteTitleSource Label: Relation Group: SrcInfo Data: https://www.ncbi.nlm.nih.gov/pubmed/30511963; http://erepository.uonbi.ac.ke/handle/11295/106532 – Name: URL Label: Availability Group: URL Data: https://www.ncbi.nlm.nih.gov/pubmed/30511963<br />http://erepository.uonbi.ac.ke/handle/11295/106532 – Name: AN Label: Accession Number Group: ID Data: edsbas.686E5322 |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsbas&AN=edsbas.686E5322 |
| RecordInfo | BibRecord: BibEntity: Languages: – Text: English Subjects: – SubjectFull: AIDS vaccine Type: general – SubjectFull: AIDS/HIV Type: general – SubjectFull: Cytokines Type: general – SubjectFull: T cells Type: general – SubjectFull: Vaccines Type: general Titles: – TitleFull: Live attenuated varicella-zoster virus vaccine does not induce HIV target cell activation. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Perciani, CT – PersonEntity: Name: NameFull: Farah, B – PersonEntity: Name: NameFull: Kaul, R – PersonEntity: Name: NameFull: Ostrowski, MA – PersonEntity: Name: NameFull: Mahmud, SM – PersonEntity: Name: NameFull: Anzala, O – PersonEntity: Name: NameFull: Jaoko, W – PersonEntity: Name: NameFull: KAVI-ICR Team – PersonEntity: Name: NameFull: MacDonald, KS IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 01 Type: published Y: 2019 Identifiers: – Type: issn-locals Value: edsbas |
| ResultId | 1 |